[go: up one dir, main page]

ECSP20029142A - Ligandos de psma para la formación de imágenes y endorradioterapia - Google Patents

Ligandos de psma para la formación de imágenes y endorradioterapia

Info

Publication number
ECSP20029142A
ECSP20029142A ECSENADI202029142A ECDI202029142A ECSP20029142A EC SP20029142 A ECSP20029142 A EC SP20029142A EC SENADI202029142 A ECSENADI202029142 A EC SENADI202029142A EC DI202029142 A ECDI202029142 A EC DI202029142A EC SP20029142 A ECSP20029142 A EC SP20029142A
Authority
EC
Ecuador
Prior art keywords
psma
imaging
endorradiotherapy
links
compounds
Prior art date
Application number
ECSENADI202029142A
Other languages
English (en)
Inventor
Alexander Schmidt
Mara Parzinger
Hans-Jürgen Wester
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of ECSP20029142A publication Critical patent/ECSP20029142A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación se refiere a la formación de imágenes y endorradioterapia de enfermedades que implican antígeno de membrana específico de próstata (PSMA). Se proporcionan compuestos que unen o inhiben PSMA y adicionalmente llevan al menos una fracción que es susceptible de radiomarcaje. También se porporcionan usos médicos de dichos compuestos.
ECSENADI202029142A 2017-12-11 2020-06-03 Ligandos de psma para la formación de imágenes y endorradioterapia ECSP20029142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17206510 2017-12-11

Publications (1)

Publication Number Publication Date
ECSP20029142A true ECSP20029142A (es) 2020-09-30

Family

ID=60654872

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202029142A ECSP20029142A (es) 2017-12-11 2020-06-03 Ligandos de psma para la formación de imágenes y endorradioterapia

Country Status (34)

Country Link
US (2) US11497819B2 (es)
EP (3) EP4464341A3 (es)
JP (3) JP7317375B2 (es)
KR (1) KR102815791B1 (es)
CN (2) CN116617421A (es)
AU (2) AU2018382479B2 (es)
BR (1) BR112020011727A2 (es)
CA (1) CA3078104A1 (es)
CL (1) CL2020001542A1 (es)
CR (1) CR20200241A (es)
CU (1) CU24677B1 (es)
CY (1) CY1125376T1 (es)
DK (2) DK3723815T3 (es)
EC (1) ECSP20029142A (es)
ES (2) ES2997266T3 (es)
FI (1) FI4008359T3 (es)
HR (2) HRP20220764T1 (es)
HU (2) HUE059083T2 (es)
IL (3) IL313103B2 (es)
JO (1) JOP20200135A1 (es)
LT (2) LT3723815T (es)
MX (2) MX2020005430A (es)
NZ (1) NZ763033A (es)
PE (1) PE20210456A1 (es)
PL (1) PL3723815T3 (es)
PT (2) PT3723815T (es)
RS (2) RS66086B1 (es)
SG (1) SG11202002965WA (es)
SI (2) SI3723815T1 (es)
SM (1) SMT202400439T1 (es)
TN (1) TN2020000072A1 (es)
UA (1) UA126413C2 (es)
WO (1) WO2019115547A1 (es)
ZA (1) ZA202003472B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4424378A3 (en) * 2017-07-28 2024-12-11 Technische Universität München Dual mode radiotracer and -therapeutics
LT3723815T (lt) 2017-12-11 2022-07-25 Technische Universität München Psma ligandai, skirti vizualizavimui ir endoradioterapijai
CA3128406A1 (en) * 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
ES2953196T3 (es) * 2019-01-30 2023-11-08 Univ Muenchen Tech Radiotrazador de modo dual de unión a PSMA y terapéutico
JP7618599B2 (ja) 2019-06-21 2025-01-21 プロビンシャル・ヘルス・サービシーズ・オーソリティ 前立腺特異的膜抗原を標的とする放射性標識化合物
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
CN113354707A (zh) * 2021-06-07 2021-09-07 苏州思萃同位素技术研究所有限公司 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品
WO2023173074A2 (en) * 2022-03-10 2023-09-14 The Research Foundation For The State University Of New York Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
WO2025022285A2 (en) 2023-07-21 2025-01-30 Novartis Ag Psma-targeting radioligand treatment regimen
WO2025029963A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [ 177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
WO2025147677A1 (en) * 2024-01-05 2025-07-10 Point Biopharma, Inc. Preparation of psma-targeted radiopharmaceutical

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888581A2 (en) 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
RU2494096C2 (ru) * 2008-08-01 2013-09-27 Дзе Джонс Хопкинс Юниверсити Агенты, связывающиеся с psma, и их применение
WO2010135431A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3536345A1 (en) 2014-05-06 2019-09-11 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
HUE065327T2 (hu) 2016-03-22 2024-05-28 Univ Johns Hopkins Prosztata-fajlagos membrán antigénhez célzott nagy affinitású szerek prosztatarák endoradioterápiájához
LT3723815T (lt) 2017-12-11 2022-07-25 Technische Universität München Psma ligandai, skirti vizualizavimui ir endoradioterapijai
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物
EA202091402A1 (ru) 2017-12-11 2020-09-01 Хелсинн Хелскеа Са Фумарат (r)-3-(1-(2,3-дихлор-4-(пиразин-2-ил)фенил)-2,2,2-трифторэтил)-1-метил-1-(1-метилпиперидин-4-ил)мочевины, способы его получения и применения

Also Published As

Publication number Publication date
KR20200097690A (ko) 2020-08-19
AU2025200837A1 (en) 2025-02-27
SMT202400439T1 (it) 2024-11-15
SG11202002965WA (en) 2020-04-29
IL274072B2 (en) 2024-11-01
HRP20241453T1 (hr) 2024-12-20
CR20200241A (es) 2020-09-21
JP2023139063A (ja) 2023-10-03
AU2018382479B2 (en) 2024-11-07
US20200297876A1 (en) 2020-09-24
BR112020011727A2 (pt) 2020-11-17
EP4464341A2 (en) 2024-11-20
EP4008359A1 (en) 2022-06-08
RU2020116158A (ru) 2022-01-13
CU20200052A7 (es) 2021-03-11
EP4464341A3 (en) 2025-01-22
DK4008359T3 (da) 2024-10-14
TN2020000072A1 (en) 2022-01-06
AU2018382479A1 (en) 2020-04-16
IL313103B1 (en) 2025-03-01
JOP20200135A1 (ar) 2020-06-02
CU24677B1 (es) 2023-09-07
SI4008359T1 (sl) 2025-03-31
PE20210456A1 (es) 2021-03-08
NZ763033A (en) 2025-02-28
EP3723815A1 (en) 2020-10-21
LT3723815T (lt) 2022-07-25
US20230122957A1 (en) 2023-04-20
JP2025011169A (ja) 2025-01-23
HUE069034T2 (hu) 2025-02-28
EP4008359B1 (en) 2024-09-11
FI4008359T3 (fi) 2024-11-11
CL2020001542A1 (es) 2020-10-02
EP3723815B1 (en) 2022-04-20
JP7572080B2 (ja) 2024-10-23
MX2023005053A (es) 2023-05-17
US11497819B2 (en) 2022-11-15
IL319022A (en) 2025-04-01
CA3078104A1 (en) 2019-06-20
CN111182927A (zh) 2020-05-19
PT4008359T (pt) 2024-10-25
ES2914832T3 (es) 2022-06-16
RS63279B1 (sr) 2022-06-30
ES2997266T3 (en) 2025-02-14
UA126413C2 (uk) 2022-09-28
RS66086B1 (sr) 2024-11-29
IL274072B1 (en) 2024-07-01
HUE059083T2 (hu) 2022-10-28
CN116617421A (zh) 2023-08-22
JP2021505532A (ja) 2021-02-18
PL3723815T3 (pl) 2022-07-18
IL313103B2 (en) 2025-07-01
LT4008359T (lt) 2024-12-27
CN111182927B (zh) 2023-07-21
IL313103A (en) 2024-07-01
KR102815791B1 (ko) 2025-05-30
JP7317375B2 (ja) 2023-07-31
WO2019115547A1 (en) 2019-06-20
CY1125376T1 (el) 2025-05-09
IL274072A (en) 2020-06-30
PT3723815T (pt) 2022-05-30
MX2020005430A (es) 2020-08-27
HRP20220764T1 (hr) 2022-09-16
ZA202003472B (en) 2022-06-29
DK3723815T3 (da) 2022-07-11
SI3723815T1 (sl) 2022-07-29

Similar Documents

Publication Publication Date Title
ECSP20029142A (es) Ligandos de psma para la formación de imágenes y endorradioterapia
MX393066B (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
DOP2018000280A (es) Compuestos moduladores de fxr (nr1h4)
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CR20190445A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
CL2023002048A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
PE20171041A1 (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion
UY33850A (es) Anticuerpos anti ? cd38
MX2017016253A (es) Anticuerpos para cd40.
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
BR112016025470A2 (pt) ?hdl terapêutico?
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
MX2018004050A (es) Inhibidores marcados con 18f mejorados del antigeno prostatico especifico de membrana (psma) y su uso como agentes de formacion de imagenes para el cancer de prostata.
MX2018015410A (es) Esteres de oxaborol y sus usos.
MX2014013678A (es) Agentes para neutralizacion de influenza.
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
CL2017000212A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
CO2018004569A2 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
MX2019002166A (es) Agonistas del receptor cxcr3.